

**Dynamics of A $\beta$  Turnover and Deposition in Different APP Transgenic Mouse Models  
Following Gamma-Secretase Inhibition**

**Abramowski, Dorothee, Karl-Heinz Wiederhold, Ulrich Furrer, Anne-Lise Jaton, Anton  
Neuenschwander, Marie-Josphine Runser, Simone Danner, Julia Reichwald, Domenico  
Ammaturo, Dieter Staab, Markus Stoeckli, Heinrich Rueeger, Ulf Neumann, Matthias Staufenbiel**  
Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland

Running title: Dynamics of A $\beta$  Turnover in APP Transgenic Mice

Corresponding author: Matthias Staufenbiel  
Novartis Pharma AG  
4002 Basel, Switzerland  
Tel: +41613249642  
Fax +41613245524  
E-mail: Matthias.Staufenbiel@novartis.com

Number of text pages: 36  
Number of tables: 1  
Number of figures: 9  
Number of references: 40  
Number of words in *Abstract*: 248  
Number of words in *Introduction*: 602  
Number of words in *Discussion*: 1596

Abbreviations: A $\beta$  Amyloid  $\beta$ ; AD Alzheimer's Disease; APP Amyloid precursor protein; BACE  $\beta$ -site APP cleaving enzyme; CSF Cerebrospinal fluid; CTF C-terminal fragment; ELISA Enzyme-linked immunosorbent assay; GFAP Glial fibrillary acidic protein; MALDI-TOF Matrix assisted laser desorption/ionization-time of flight mass spectrometry; PS Presenilin; TBS Tris buffered saline

Recommended section assignment: Neuropharmacology

### Abstract

Human  $\beta$ -amyloid precursor protein (APP) transgenic mice are commonly used to test potential therapeutics for Alzheimer's disease (AD). We have characterized the dynamics of  $\beta$ -amyloid ( $A\beta$ ) generation and deposition following  $\gamma$ -secretase inhibition with compound LY-411575. Kinetic studies in pre-plaque mice distinguished a detergent soluble  $A\beta$  pool in brain with rapid turnover (half-lives for  $A\beta_{40}$  and  $A\beta_{42}$  were 0.7 and 1.7 h) and a much more stable, less soluble pool.  $A\beta$  in cerebrospinal fluid (CSF) reflected the changes in the soluble brain  $A\beta$  pool, while plasma  $A\beta$  turned over more rapidly. In brain APP C-terminal fragments (CTF) accumulated differentially. The half-lives for  $\gamma$ -secretase degradation were estimated as 0.4 and 0.1 h for C99 and C83, respectively. Three different APP transgenic lines responded very similarly to  $\gamma$ -secretase inhibition regardless of the familial Alzheimer's disease mutations in APP. Amyloid deposition started with  $A\beta_{42}$  while  $A\beta_{38}$  and  $A\beta_{40}$  continued to turn over. Chronic  $\gamma$ -secretase inhibition lowered amyloid plaque formation to a different degree in different brain regions of the same mice. The extent was inversely related to the initial amyloid load in the region analyzed. No evidence for plaque removal below baseline was obtained.  $\gamma$ -secretase inhibition led to a redistribution of intracellular  $A\beta$  and an elevation of CTFs in neuronal fibers. In CSF  $A\beta$  showed a similar turnover as in pre-plaque animals demonstrating its suitability as marker of newly generated, soluble  $A\beta$  in plaque-bearing brain. This study supports the use of APP transgenic mice as translational models to characterize  $A\beta$  lowering therapeutics.

## Introduction

Deposits of the A $\beta$  peptide known as amyloid plaques are one of the defining pathological hallmarks of Alzheimer's disease and aggregated A $\beta$  species are considered to play a key role in disease pathogenesis (Hardy and Selkoe, 2002). Generation of A $\beta$  from the membrane-bound  $\beta$ -amyloid precursor protein (APP) involves consecutive cleavage by the  $\beta$ -secretase, BACE1 and the  $\gamma$ -secretase complex (Wolfe, 2006). BACE catalyzes the cleavage at the N-terminus of A $\beta$ , releasing a soluble form of APP (sAPP $\beta$ ), and leaving a C-terminal fragment (C99) in the membrane. C99 is then processed by  $\gamma$ -secretase, which possibly involves three successive cleavage steps (Zhao et al., 2005) finally yielding a set of A $\beta$  peptides heterogeneous at the C-terminus, with the most abundant ends at positions 40, 42 and 38. The other product of this cleavage is the APP intracellular domain thought to be a regulator of gene expression (Wolfe, 2006). The  $\gamma$ -secretase is a complex composed of presenilins (PS1 or PS2), nicastrin, presenilin enhancer-2 (PEN-2) and APH-1. Considerable evidence suggests that the presenilins contain the active site of this intramembrane aspartyl protease (Wolfe, 2006). A large number of presenilin mutations are associated with familial AD (Tandon and Fraser, 2002). They usually shift the A $\beta$  generation to the longer A $\beta$ 42 isoform as demonstrated in cellular and transgenic models (Citron et al., 1997) as well as in AD patients (Scheuner et al., 1996).  $\gamma$ -secretase was shown to also cleave a number of other type I transmembrane proteins (Selkoe and Kopan, 2003), the best characterized one being Notch, an important regulator of cell fate. Accordingly, mice deficient in PS1 (Wong et al., 1997) or nicastrin (Li et al., 2003) are not viable, while PS2-KO mice survive and lack an overt phenotype (Donoviel et al., 1999).

Because of its pivotal role in A $\beta$  generation,  $\gamma$ -secretase has been a target of drug development and several substances have been described to inhibit  $\gamma$ -secretase in vitro (Shearman et al., 2000; Dovey et al., 2001), in rats (Best et al., 2005), in guinea pigs (Anderson et al., 2005) and in several APP transgenic mouse models of Alzheimer's disease (Dovey et al., 2001; Cirrito et al., 2003; Lanz et al., 2004; Wong et al., 2004; Anderson et al., 2005; Barten et al., 2005; Best et al., 2005; Churcher et al., 2006; Best et al., 2007). Inhibition of  $\gamma$ -secretase in rodents resulted in a substantial reduction of A $\beta$  in brain and

cerebrospinal fluid (CSF) within a few hours after substance application. In several *in vivo* models A $\beta$  reduction by either  $\gamma$ -secretase inhibition or conditional presenilin knockout was accompanied by a beneficial effect on cognitive function (Comery et al., 2005; Dash et al., 2005; Saura et al., 2005). However, severe side effects concerning lymphatic and intestinal cell differentiation have been observed for  $\gamma$ -secretase inhibitors seemingly due to inhibition of Notch cleavage (Searfoss et al., 2003; Wong et al., 2004). Application to humans has been described for one  $\gamma$ -secretase inhibitor only, which showed reduction of A $\beta$  in plasma, but not in CSF (Siemers et al., 2007).

In this study we used the  $\gamma$ -secretase inhibitor LY-411575 (May et al., 2001) to characterize the dynamics of A $\beta$  in brain, CSF and plasma in several APP transgenic mouse models before onset of amyloid plaque formation. The corresponding changes in the  $\gamma$ -secretase substrates, the APP C-terminal fragments, were analyzed in comparison. Subfractionation of brain was used to distinguish A $\beta$  populations with different turnover. We also analyzed the effect of chronic reduction of A $\beta$  production in a preventive as well as a therapeutic paradigm, i.e. in pre-plaque and plaque-bearing mice. Our study describes key characteristics of A $\beta$  generation and deposition in APP transgenic mice.

## Methods

*Experimental animals*- The transgenic mouse lines used express human APP751 under the control of the murine Thy1-promoter, resulting in neuron specific expression. APP23 mice (Sturchler-Pierrat et al., 1997) express APP with the KM670/671NL “Swedish” mutation. In APP24 mice the “Swedish” double mutation was combined with the “London” mutation V717I. APP51/16 mice express wildtype APP (Herzig et al., 2004). APP23 and APP51/16 overexpress human APP about 7 and 10 times over endogenous APP. Mostly compact amyloid plaques start appearing at the ages of about 6 and 12-15 months, respectively. In APP24 mice, overexpression of human APP is about 3.5-fold. Mostly diffuse amyloid plaques start appearing at 8 months of age. The mice were on a C57BL/6 background and hemizygous for the transgene. All animal experiments were in compliance with protocols approved by the Swiss Animal Care and Use Committees.

JPET#140327

*Substance application and brain concentration-* The  $\gamma$ -secretase inhibitor N<sup>2</sup>-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N<sup>1</sup>-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575; for chemical structure see Wong et al., 2004) was used. Mice received vehicle alone (0.25% methylcellulose in water) or 1-10 mg/kg LY-411575 suspended in vehicle solution by oral gavage at 20 ml/kg. The following compound concentrations [mean $\pm$ SD in nM] were determined in brain after treatment of male mice with 10 mg/kg LY-411575: 0.5 h, 111 $\pm$ 45; 1 h, 83 $\pm$ 8; 2 h, 52 $\pm$ 6; 4 h, 33 $\pm$ 4; 6 h, below limit of quantification. For comparison, the cellular IC<sub>50</sub> value of LY-411575 is about 0.1 nM (Wong et al., 2004 and our unpublished results with APP23 and APP51/16 primary neurons).

*Mouse sacrifice and tissue sampling-* CSF was sampled from the cisterna magna under anesthesia with 3% isoflurane. In most cases 3-10  $\mu$ l of CSF could be obtained. Mice were decapitated and EDTA-plasma was prepared from the blood. In experiments with chronic substance treatment, one brain hemisphere was fixed by immersion in 4% formaldehyde solution. For biochemical investigation, forebrain was prepared from the second hemisphere by removal of olfactory bulb and hindbrain, frozen on dry ice and stored at -80°C until used. After chronic treatment of APP24 mice, the olfactory bulb and the pons/medulla oblongata from one brain hemisphere were also isolated and frozen on dry ice.

*Homogenization of brain tissue-* Brain regions were weighed and homogenized by sonication in 10 volumes of Tris-buffered saline (TBS; 20 mM Tris-HCl pH 7.6, 137 mM sodium chloride, protease inhibitor cocktail Complete, Roche Diagnostics, Mannheim, Germany).

*Determination of APP and its metabolites-* A $\beta$  was quantified using different methods (Western blotting, quantitative MALDI-TOF, ELISA and an electrochemiluminescence linked immunoassay). To obtain standards for the quantifications, dilution series of the analytes [synthetic A $\beta$ 1-38/40/42 peptides (Bachem, Torrance, CA and r-Peptide, Bogart, GA), recombinant sAPP $\alpha$  and sAPP $\beta$  (Meso Scale Discovery, Gaithersburg, MD), APP (in transgenic mouse brain homogenates)] were prepared in non-transgenic mouse brain extract or plasma. The presence of non-transgenic CSF had no influence on ELISA calibration curves from synthetic A $\beta$  standards. Therefore standards for determination of CSF A $\beta$

were prepared without addition of CSF from non-transgenic mice.

*Immunoprecipitation of A $\beta$* - For immunoprecipitation of A $\beta$  from brain tissue, homogenates were extracted with 1% sodium dodecyl sulfate at 95°C for 3 min, diluted with 9 volumes of TBS and cleared by centrifugation. A $\beta$  peptides were immunoprecipitated using the monoclonal antibody  $\beta$ 1 reacting with an epitope near the amino-terminus of A $\beta$  (Schrader-Fischer and Paganetti, 1996) and protein G coated magnetic beads (Dynal Biotech, Hamburg, Germany). Antibody  $\beta$ 1 does not recognize rodent A $\beta$  under the conditions used. For immunoprecipitation of A $\beta$  from plasma, antibody  $\beta$ 1 covalently coupled to sepharose beads was used.

*Dephosphorylation of APP C-terminal fragments*- Forebrain homogenates were supplemented with 1% Nonidet P-40 (Fluka, Buchs, Switzerland), 50 mM HEPES (pH 7.5), 0.1 mM Na<sub>2</sub>EDTA, 5 mM dithiothreitol, 0.01% Brij 35, 3 mM MnCl<sub>2</sub> and were incubated with E.coli  $\lambda$ -phosphatase (New England Biolabs, Ipswich, MA, 400 units per mg forebrain) at 30°C for 1 hour. The reaction was stopped by addition of SDS sample buffer.

*Gel electrophoresis and Western blotting*- For detection of A $\beta$ , immunoprecipitates, CSF or brain homogenates were separated on 10% Tris-bicine acrylamide gels with 8 M urea as described (Klafki et al., 1996). C-terminal APP fragments were separated on 10% or 13% Tris-bicine acrylamide gels without urea and were detected with rabbit antiserum APP-C8 raised against the carboxy-terminal amino acids of APP (Schrader-Fischer and Paganetti, 1996). Transgene derived APP and A $\beta$  were detected with the human-specific monoclonal antibody 6E10 (Signet, Dedham, MA). Total APP was detected with antibody 22C11 (Roche Molecular Biochemicals, Rotkreuz, Switzerland). The bands obtained on films were quantified using the software MCID (version M7 elite, InterFocus Imaging Ltd, Cambridge, England). Some of the CSF samples analyzed by Western blotting (Figure 5) were slightly contaminated with blood, and globin comigrated with A $\beta$ 1-38 on the gel, which precluded quantification of the A $\beta$ 1-38 band. For detection of presenilin 1, forebrain homogenates from 5 animals per group were separated on 13% Tris-glycine acrylamide gels and PS1 CTFs were detected on Western blots with antibody R28 (Baumann et al., 1997) directed against the large cytoplasmic loop of presenilin 1.

JPET#140327

*A $\beta$  quantification by MALDI-TOF-* A $\beta$  immunoprecipitated with antibody  $\beta$ 1 and protein G coated magnetic beads as described above was eluted with a acetonitrile/water/formic acid solution (50:40:10, v/v/v) saturated with  $\alpha$ -cyano-4-hydroxy-cinnamic acid. As internal standard, 10 pM bovine insulin was added. Samples were loaded on a MALDI-TOF target plate (Applied Biosystems, Framingham, MA) and dried at ambient temperature. Mass spectra were acquired in the mass range 3000 to 6000 Dalton using an Applied Biosystems Voyager-DE sSTR TOF mass spectrometer. A $\beta$  peptides were located on the spectra by identifying the most prominent peak in a region of  $\pm 5$  Dalton of the calculated mass of each peptide. For quantification, the peak height was used, as the area under the curve yielded less reliable results, when irrelevant peaks were present adjacently.

*A $\beta$  quantification by ELISA-* For determination of total A $\beta$ 40 or A $\beta$ 42, forebrain homogenates were extracted for 15 min at 4°C with 70% formic acid. The extracts were neutralized by addition of 19 volumes 1 M Tris-base and centrifuged for 15 min at 20 000xg. For pre-plaque mice, the supernatant was directly applied to ELISA plates (IBL Human Amyloid  $\beta$  (1-40) JP27713 or (1-42) JP27711 Assay, IBL, Hamburg, Germany and Innostest  $\beta$ -Amyloid 1-42 #80177 Assay, Innogenetics, Gent, Belgium). When forebrains with high plaque load were analyzed, the extracts were further diluted in 70% formic acid, neutralized and diluted in sample dilution buffer from the ELISA kit, as necessary to achieve an A $\beta$  concentration within the standard curve. For analysis of TBS soluble A $\beta$ , forebrain homogenates were centrifuged at 100 000xg for 15 min. For Triton X-100 soluble A $\beta$ , Triton X-100 was added to the forebrain homogenate (final concentration 1%) and samples were extracted on ice for 15 min before centrifugation at 100 000xg. Samples were mixed every 5 min. The supernatants were diluted (total dilution 1:80) with sample dilution buffer from the ELISA kit (see above), as undiluted extracts caused high background and a low signal to noise ratio. For determination of A $\beta$  in CSF, the IBL Human Amyloid  $\beta$  (1-40) and the Innostest  $\beta$ -Amyloid 1-42 assays were used.

*A $\beta$  quantification by electrochemoluminescence-linked immunoassay-* MSD 96-Well MULTI-ARRAY Human (6E10) Abeta 40 or Abeta 42 Ultra-Sensitive Kits were used (Meso Scale Discovery, Gaithersburg, MD). For A $\beta$ 40 determination in plasma samples were cleared by centrifugation (1 min,



20 000xg), mixed with an equal volume of 3% Blocker A solution included in the assay kit and further processed according to the manufacturers instructions. Signals were measured on a SECTOR™ Imager 6000 reader (Meso Scale Discovery). Triton-X-100 soluble A $\beta$  was prepared as described for ELISAs and diluted to a final dilution of 1:100 with 3 % Blocker A. This method was also used to verify the A $\beta$  reductions in some experiments and the A $\beta$  concentrations by direct comparison of all pre-plaque control groups.

*Determination of sAPP $\alpha$  and sAPP $\beta$  by electrochemoluminescence-linked immunoassay-* Forebrain homogenates were extracted with 1% Triton X-100 on ice for 15 min. Samples were centrifuged (15 min, 4°C, 20 000xg). The supernatants were further diluted with 1% Triton X-100 in TBS (total dilution 1:2000), loaded on a MS6000 sAPPalpha/sAPPbeta multiplex plate (Meso Scale Discovery) and further processed as described for A $\beta$ .

*Estimation of A $\beta$  and CTF half-life and production rate-* The time course of A $\beta$  concentrations after  $\gamma$ -secretase inhibition is described by the equation

$$[A\beta]_t = [A\beta]_0 * e^{(-k*t)} + \text{offset} \quad (\text{Eq. 1})$$

where [A $\beta$ ]<sub>t</sub> and [A $\beta$ ]<sub>0</sub> are the concentrations of A $\beta$  at time t and start (in vehicle treated mice), respectively. k is the first-order rate constant of A $\beta$  removal, and offset is the amount of A $\beta$  not affected by treatment. Data pairs (t, [A $\beta$ ]<sub>t</sub>) were fitted to the above equation to determine k (Origin 7.5 software, Origin lab corporation, Northampton, MA). The half-life was calculated using

$$t_{1/2} = \ln 2/k \quad (\text{Eq. 2}).$$

Under steady-state conditions, which can be assumed to exist in pre-plaque mice, the rate of production, k' of A $\beta$  equals its rate of clearance. It can be calculated from

$$k' = k * ([A\beta]_0 - \text{offset}) \quad (\text{Eq. 3}).$$

An independent estimate of A $\beta$  production rates was obtained from average A $\beta$  loads measured in 11 and 18.3 months old APP23 mice with the formula:

$$k' = \frac{[A\beta]_{18.3 \text{ mo}} - [A\beta]_{11 \text{ mo}}}{18.3 \text{ mo} - 11 \text{ mo}} \quad (\text{Eq. 4}).$$

Half-lives of C99 and C83 were estimated based on their relative concentration in vehicle treated mice (steady state concentration) and their production rates  $p$  (increase of concentration per time as determined between 0.5 and 2 h after substance treatment) according to:

$$t_{1/2} = \text{steady state concentration} * \ln 2 / p \quad (\text{Eq. 5})$$

*Immunocytochemistry*- Formaldehyde fixed brain halves were embedded into paraffin and sagittally cut into 4  $\mu\text{m}$  sections at three different anatomical levels. Sections were processed as described (Sturchler-Pierrat et al., 1997) and immuno-histochemically stained with antibodies.  $A\beta$  specific antibodies were rabbit serum NT11 for total  $A\beta$  and end specific mouse monoclonal antibodies 25H10 for  $A\beta_{40}$  and 29C12 for  $A\beta_{42}$  (a gift of P. Paganetti). APP was stained with rabbit sera APP474 raised against purified secreted APP from rat cells or with APP-C8. Glial fibrillary acidic protein (GFAP) as a marker of astrocytes was detected with a rabbit antiserum (Dako M0761, Dako, Glostrup, Denmark). The microglia cells were stained with rabbit antiserum Iba1 obtained from Wako Chemicals (Cat 019741). Bound antibody was visualized by using the avidin-biotin-peroxidase technique (ABC-Elite Kit PK6100; Vector Laboratories, Burlingame, CA). Finally, sections were reacted with diaminobenzidine (DAB) metal enhanced substrate (# 1718096, Roche, Penzberg, Germany) and counterstained with hemalum.

*Amyloid plaque load quantification*- Amyloid plaque load as % of total area and plaque numbers were measured in neocortex and caudate putamen of NT11 stained sections at three different anatomical levels using a microcomputer assisted imaging software (MCID, version M7 elite, InterFocus Imaging Ltd, Cambridge, England). Microscopic images were digitized by use of a Roper black and white CCD TV camera and stored with 1124x1124 pixel resolution at 256 gray levels. Diffuse amyloid was captured with a detail enhancing function of the software. The pixel size was calibrated using an object micrometer at 5x magnification (Leica Neoplan Objective). Using a motor driven microscope stage for exact positioning of adjacent object fields the entire brain region was analyzed. For each object field the anatomical area

was defined by manual outline. Isolated tissue artifacts were excluded by manual outline.

*Statistical analyses-* For analysis of APP and its C-terminal fragments, of soluble A $\beta$  and of total A $\beta$  in pre-plaque mice, Student's t-tests (usually 1-tailed) or analysis of variance (ANOVA) followed by post hoc analysis were done (Tukey's test for pairwise comparison of all groups or 1-tailed Dunnett's test for comparison of all treated groups to vehicle). To compare magnitudes of the substance effect on different A $\beta$  species or between different extractions, ANOVA and 1-tailed Dunnett's test were performed on the decadic logarithm of the ratio of the two values. As amyloid loads in plaque bearing mice do not usually show a normal distribution, we used non-parametric tests for these data (Mann-Whitney U-test or the Kruskal-Wallis test followed by post-hoc Tukey's test on ranks;  $p < 0.05$  considered significant for all tests, analyses done with Systat for Windows 11, Systat Software Inc., San Jose, CA).

## Results

The compound used in this study, LY-411575 has previously been described (May et al., 2001; Wong et al., 2004). To determine optimal inhibition, pre-plaque APP23 mice expressing human APP with the KM670/671NL "Swedish" mutation received oral doses between 1 and 10 mg/kg of LY-411575 (supplementary data, Figure 1S). The highest dose of 10 mg/kg was slightly more effective than 3 mg/kg and was chosen for further acute studies.

*Kinetics of A $\beta$  and CTFs in pre-plaque APP23 mice after a single  $\gamma$ -secretase inhibitor dose.* To analyze the kinetics of A $\beta$  removal *in vivo*, pre-plaque APP23 mice received a single oral dose of 10 mg/kg LY-411575. Following sacrifice at different times thereafter, total A $\beta$  concentrations in forebrains were determined after formic acid extraction whereas CSF and plasma A $\beta$  were analyzed directly. Reduced A $\beta$ 40 concentrations were observed in all three compartments as early as 30 min following treatment (Figure 1, A). Thereafter, A $\beta$ 40 continued to decrease reaching a minimum at 4-8 h. CSF and plasma A $\beta$ 40 decreased faster and to a lower minimum than total A $\beta$ 40 in forebrain. Even at 24 h the A $\beta$ 40 concentrations in forebrain (-57%,  $p < 0.001$ ) and CSF (-48%,  $p < 0.01$ ) remained below vehicle values. Of note in plasma A $\beta$ 40 recovered more rapidly. At 8 h its concentration was only 18% below vehicle,

JPET#140327

compared to at least 80% for CSF and forebrain A $\beta$ 40. Thereafter no difference from vehicle treated animals was detectable in plasma. Total A $\beta$ 42 in forebrain was less reduced than A $\beta$ 40 at all time points up to 24 h (significant between 2 h ( $p=0.01$ ) and 8 h ( $p<0.001$  Figure 1, B). However, 53 h after treatment a significant (-19%,  $p<0.01$ ) reduction persisted, while A $\beta$ 40 was back to vehicle concentrations. The kinetic difference between the A $\beta$  peptides was confirmed in a separate experiment, where A $\beta$  was analyzed by Western blotting (data not shown). In another study the substance was applied intravenously (1 mg/kg), which did not further accelerate the reduction of A $\beta$  in forebrain (data not shown).

The effect of  $\gamma$ -secretase inhibition on APP C-terminal fragments was analyzed on Western blots of forebrain homogenates (Figure 1, C). For C99 a gradual increase was apparent already at 30 min but leveled off rapidly to reach a maximum at 8 h. After 24 h C99 was still elevated while it had declined to vehicle values at 53 h. In contrast, C83 showed a lag phase followed by a longer increase reaching a maximum at 8-24 h. This demonstrates inhibition of  $\gamma$ -secretase at least until 8 h. Even at 53 h C83 remained considerably above vehicle levels. Overall, the relative increase of C83 was larger than that of C99.

*Similar reduction of A $\beta$  following  $\gamma$ secretase inhibition in APP24 and APP51/16 mice.* To test for potential differences between transgenic lines, we analyzed APP24 mice containing the “London” mutation (V717I) in the  $\gamma$ -secretase cleavage region of APP (in addition to the KM670/671NL mutation). Compared to APP23 these mice show the expected increased A $\beta$ 42/40 ratio but generate less APP and total A $\beta$ . Forebrain and CSF A $\beta$  were measured at 1 h and 6 h after a 10 mg/kg LY-411575 treatment of pre-plaque APP24 mice (Figure 2, A). Total A $\beta$ 40 and A $\beta$ 42 were significantly reduced already after 1 h. At both time points, the relative decrease of each of the A $\beta$  species was very similar to the one in APP23 mice (Figure 1, A). The smaller reduction of A $\beta$ 42 compared to A $\beta$ 40 found in APP23 was confirmed ( $p<0.05$  at 6 h). Average A $\beta$ 42 in CSF ( $1.0\pm 0.1$  pmol/ml) was reduced by 33% ( $p<0.05$ ) at 1 h and 89% ( $p<0.001$ ) at 6 h, which is a stronger reduction than in forebrain, similar to the observation made for A $\beta$ 40 in APP23.

JPET#140327

We also studied mice expressing human wild-type APP (pre-plaque APP51/16) treated with 10 mg/kg LY-411575 and sacrificed 6 h later (Figure 2, A). Forebrain showed a 66% decrease in A $\beta$ 40 following formic acid extraction, very similar to APP24. For A $\beta$ 42 a reduction was also found but could not be quantified reliably. In plasma, A $\beta$ 1-40 was reduced by 89% ( $p < 0.01$ ). These data demonstrate that the three different APP transgenic mouse lines carrying different mutations respond with similar A $\beta$  reductions to the acute inhibition of  $\gamma$ -secretase.

*Differential extraction of a brain A $\beta$  subpopulation undergoing rapid turnover.* The maximal reduction of total A $\beta$ 40 or A $\beta$ 42 achieved after  $\gamma$ -secretase inhibition was lower in brain than in CSF. Considering that CSF A $\beta$  originates from brain, this observation hints to brain A $\beta$  species, which undergo a slower turnover resulting in an incomplete removal. We tried to enrich a subpopulation of A $\beta$ , which is completely removed upon acute  $\gamma$ -secretase inhibition. Forebrains of APP23 mice from the kinetic study were extracted either with formic acid, 1% Triton X-100 or TBS and A $\beta$ 40 was quantified (Figure 1, A). In vehicle treated mice, Triton X-100 extracted ~30% and TBS extracted ~2% of total, formic acid soluble A $\beta$ 40. The relative reduction of A $\beta$ 40 was stronger in the Triton X-100 extract than in the formic acid extract at all time points of the descending part of the kinetics ( $p = 0.05$  at 4 h and  $p = 0.016$  at 6 h). The kinetics of A $\beta$ 40 in Triton X-100 extracts closely reflected those of CSF. In the TBS extracts the reduction of A $\beta$ 40 was even higher than in Triton X-100 extracts, however, the variation was larger (Figure 1, A). Confirming these observations LY-411575-treated APP24 and APP51 mice also showed a stronger A $\beta$ 40 reduction in the Triton X-100 compared to the formic acid extract (Figure 2, A).

APP24 mice were used to test for an enrichment of an A $\beta$ 42 population with a more rapid turnover. Triton X-100 soluble forebrain A $\beta$ 42 was more reduced after LY-411575 treatment than total, formic acid extracted A $\beta$ 42 (Figure 2, A;  $p < 0.05$  at 1 h) and paralleled A $\beta$ 42 in CSF better, similar to A $\beta$ 40 in APP23. A larger A $\beta$ 42 reduction in the Triton X-100 extract (-33% at 1 h, below limit of quantification at 6 h) compared to the formic acid extract (Figure 1, B) was also observed for APP23 mice. These results indicate that subpopulations of A $\beta$ 40 and A $\beta$ 42 exist in brain of pre-plaque APP transgenic mice, which

differ in stability. They also confirm the similarity of the A $\beta$  reduction in the different transgenic mouse models following  $\gamma$ -secretase inhibition.

*Estimation of A $\beta$  half-life and production rate.* The decrease of A $\beta$  after  $\gamma$ -secretase blockade allowed us to estimate its half-life by fitting data from the initial inhibition period (Figure 2, B and 3, A) using a first-order model for A $\beta$  reduction (see Methods, Eq. 1). This approach assumes immediate and complete block of A $\beta$  generation, in agreement with brain substance levels being several orders of magnitude above cellular IC<sub>50</sub> values (see Methods). The calculated values are upper limits of the half-life, however, the good fit indicates that  $\gamma$ -secretase inhibition was obtained rapidly. For APP23 mice the half-life of formic acid extracted, total A $\beta$ 40 in forebrain was determined as 1.1 h. This predicts an almost complete disappearance after 4 h, which was not observed, likely reflecting the presence of A $\beta$  subpopulations with considerably longer half-lives. Triton X-100 soluble A $\beta$ 40 disappeared with a half-life of 0.7 h and obviously reflects a population with a more rapid turnover. The same value was obtained for CSF A $\beta$ 40. Its almost complete loss after 4 h suggests the presence of only one A $\beta$ 40 population likely reflecting the soluble and removable fraction of brain A $\beta$ 40. The A $\beta$ 40 half-life in plasma was calculated as 0.5 h based on a simple first order decline (Figure 3, A), but may be shorter assuming an initial lag phase suggested by the 30 min time point.

For formic acid extracted brain A $\beta$ 40 from APP24 mice, a shorter half-life (1.3 h) was calculated than for A $\beta$ 42 (2 h) (Figure 2, B). The amount of A $\beta$ 42 left after 6 h (50%) was far more than predicted from this half-life (12.5%) concurring with the presence of more stable A $\beta$ 42 species as well. However, A $\beta$ 42 in Triton X-100 brain extracts showed a faster turn-over ( $t_{1/2} = 1.7$  h) with the same half-life as A $\beta$ 42 in CSF. As the brain concentration of A $\beta$  remains about constant in pre-plaque APP transgenic mice, a steady-state between generation and removal of A $\beta$  can be assumed. This allows to estimate the approximate A $\beta$  production rate in forebrain of APP23 mice as 9.3 pmol/g/h for A $\beta$ 40 and 0.7 pmol/g/h for A $\beta$ 42 (see Methods, Eq. 3). To test the plausibility of these values, we made the simplifying assumption that newly generated A $\beta$  is quantitatively deposited during the phase of exponential plaque growth. We measured

JPET#140327

average forebrain A $\beta$  in female APP23 mice at 11 and 18.3 months as 5447 and 65653 pmol/g (A $\beta$ 1-40) and as 1668 and 9820 pmol/g (A $\beta$ 1-42), respectively. The increase of A $\beta$  concentrations over time allows to roughly estimate the production rates of A $\beta$ 40 and 42 in APP23 forebrain as  $k' = 11$  pmol/g/h and 1.5 pmol/g/h, respectively (Methods, Eq. 4). These values are in good agreement with production rates calculated from the A $\beta$  removal kinetics. Overall, these estimations indicate a half-life for soluble, non-deposited A $\beta$ 40 and 42 of about 0.7 and 1.7 hours or even less. Additional species exist in brain (e.g. A $\beta$  bound to proteins or molecules in an oligomeric state) with a much longer half-life, which remains to be determined.

The kinetics of APP carboxy-terminal fragments after blockade of  $\gamma$ -secretase were also used to estimate their degradation by this enzyme. We first determined the production rates for both C83 and C99 from the increase between 0.5 and 2 h, This interval accounts for a possible initial lag phase (Figure 3, B). As described in Methods (Eq. 5), the half-lives of C99 and C83 for degradation by  $\gamma$ -secretase were then calculated as about 0.4 and 0.1 h, respectively.

*Subchronic inhibition of  $\gamma$ -secretase in pre-plaque APP23 mice.* To study the effects of longer  $\gamma$ -secretase inhibition, pre-plaque male APP23 mice were treated for two weeks once daily with 10 mg/kg LY-411575 without signs of overt toxicity. A second set of animals received only a single dose. Mice were sacrificed 6 h or 24 h after the last substance application. Brain A $\beta$  levels were significantly more reduced after the 14 day than after a single treatment at the 6 hr sacrifice point (supplementary data, Figure 2S). This additive effect is consistent with the observation that a single inhibitor dose reduced A $\beta$  for longer than the treatment interval of 24 h (Figure 1). Six and 24 h after the last of 14 substance applications, forebrain A $\beta$ 40 was decreased by 94% and 55%, while the A $\beta$ 42 reduction reached 89% and 32%, respectively. CTFs accumulated differentially. While the C99 increase in the forebrain was only slightly higher than after a single treatment, the C89/C83-band was considerably stronger after the 14 day treatment (Figure 4, A). Dephosphorylation allowed to identify C83 as the main polypeptide in this band. (Figure 4, C). These data indicate that  $\gamma$ -secretase was still efficiently inhibited after subchronic LY-

411575 treatment.

*Chronic inhibition of  $\gamma$ secretase in APP23 mice during the early phase of amyloid plaque formation.*

Using a preventive paradigm we next tested if chronic reduction of A $\beta$  production also reduced amyloid plaque formation. Female APP23 mice (20 per group) were treated for 3 months with LY-411575 and sacrificed at 6 h and 24 h after the last treatment. Treatment was started at an age of six months, when plaque formation just begins. Mice received 10 mg/kg/d of drug for 7 days and 3 mg/kg thereafter to improve tolerability because after the first week two (10%) substance treated animals showed weight reduction, sickness behavior and were lost. The side effects were not further analyzed but may have been related to intestinal goblet cell hyperplasia (Wong et al., 2004; Hyde et al., 2006). The body weight of the remaining animals was not reduced during chronic treatment and developed similarly to the non-treated controls. Yet, after about 14 days grey patches started to appear in the normally black coat of substance treated animals (supplementary data, Figure 3S, C) and thymus atrophy was found at sacrifice (data not shown) as previously described (Wong et al., 2004; Hyde et al., 2006). The average forebrain weight of the treated animals was slightly reduced by about 5% ( $p < 0.05$ ) and a 2.7 times larger volume of CSF could be collected from these animals ( $p < 0.001$ , supplementary data, Figure 3S, B).

Analysis of total A $\beta$  from forebrains showed that all isoforms measured (A $\beta$ 1-38, 40 and 42) were reduced by about 80% following LY-411575 treatment (Figure 5). Data from the subgroups sacrificed 6 and 24 h after the last treatment were pooled as they did not differ significantly. Nonetheless, a trend for higher total A $\beta$  values at the 24 h time point indicated an additional, small contribution of the acute reduction of newly synthesized A $\beta$ . As after the shorter treatments, accumulated C-terminal APP fragments were found (Figure 4). The strongest accumulation was found for C83 while C89 remained a minor portion of the accumulated CTFs (Figure 4, C). Very similar to acute LY-411575 treatment, A $\beta$ 1-38, A $\beta$ 1-40 and 1-42 concentrations in CSF were reduced by about 85%, 78% and 61%, respectively, 6 h after the last substance application (Figure 5, B). A significant reduction of A $\beta$  in CSF by 30% (A $\beta$ 1-38), 43% (A $\beta$ 1-40) and 52% (A $\beta$ 1-42) was still seen at 24 h. In plasma, analyzed 6 h after the last substance



application, all three A $\beta$  species (A $\beta$ 1-38, 40 and 42) were reduced by about 80% in LY-411575 treated animals (not shown).

To test for an effect of the treatment on APP expression and its metabolism we quantified total APP (full-length plus sAPP) and sAPP $\alpha$  and sAPP $\beta$ . Total APP on Western blots was slightly decreased in substance treated animals (-13%,  $p=0.008$ , 2-tailed t-test). Average levels of sAPP $\alpha$  ( $15\pm 1$   $\mu\text{g/g}$  in controls) and sAPP $\beta$  ( $53\pm 5$   $\mu\text{g/g}$  in controls) were also significantly reduced (-6%,  $p<0.01$  and -18%,  $p<0.001$ , respectively, 2-tailed t-test). While these changes may indicate a general treatment effect, they are much smaller than the A $\beta$  reductions observed in the different compartments. We also tested for a compensatory upregulation of presenilin during the long-term  $\gamma$ -secretase inhibition and probed forebrain Western blots with antibodies against the presenilin 1 CTF, but did not detect a difference between the LY-411575 and vehicle group (data not shown).

Quantitative immunohistochemistry of the neocortical amyloid load revealed no difference between animals sacrificed at 6 or 24 h after the last treatment, hence both groups were combined for analysis. Compared to the vehicle treated animals, a 80% reduction of the neocortical plaque area was found in the treated group (Figure 6, A-D), which was identical in size to the biochemically determined effect. While the neocortical area covered by plaques exceeded 0.1% in 65% of the vehicle treated animals, all mice receiving LY-411575 had a plaque area below 0.1%. The median cortical plaque number was reduced by 66% from 4.6 to 1.6 plaques per  $\text{mm}^2$ , i.e. less than the median plaque area in agreement with a stronger effect on A $\beta$  deposition than on de novo plaque formation.

Following 3 months of LY-411575 treatment, a morphological change of intra-neuronal A $\beta$  was observed in cortical pyramidal cells. Whereas the A $\beta$  distribution was mostly homogeneous in control mice, treated animals showed strongly stained clusters (Figure 6, E, F). This change in A $\beta$  distribution was found in cerebral cortex and subiculum, regions forming the first amyloid plaque deposits. It was not observed in the hippocampus proper, where plaque formation starts somewhat later. End-specific A $\beta$ 40 and A $\beta$ 42 antibodies also reacted with these clusters (supplementary data, Figure 4S) confirming their A $\beta$  content rather than a cross-reaction with APP. Consistent with this notion, staining of neuronal cell bodies for

JPET#140327

APP with antibodies recognizing its N- or C-terminus was reduced in LY-411575 treated animals (Figure 7). This included neocortical as well as hippocampal neurons, suggesting a reduction of APP in certain brain regions of treated animals, in accordance with the reduced APP measured biochemically. In contrast, APP C-terminal antibodies strongly stained nerve fibers in several brain regions of LY-411575 treated animals (Figure 7, B, D). This staining most likely reflected accumulated C-terminal fragments of APP rather than full length APP, as these structures were not stained by a N-terminal APP antibody (Figure 7, E, F).

To analyze for an effect on plaque-associated gliosis, we quantified astrocyte (GFAP) and microglia (Iba1) stainings. At the low amyloid plaque load in 9 months old APP23 mice, these markers were not generally increased compared to non-transgenic animals but rather redistributed resulting in an association with plaques. Accordingly, the GFAP and Iba1 labeled surface areas in cerebral cortex or hippocampus remained unchanged by the treatment. However, the Iba1 positive area was increased (+31%,  $p=0.01$ , 2-tailed t-test) in the cerebellum of LY-411575 treated mice indicating some microglia activation. This probably is a substance effect unrelated to the plaque reduction, as plaques are not formed in cerebellum of APP23 mice.

*Chronic  $\gamma$ -secretase inhibition of plaque bearing mice.* As AD patients already contain amyloid deposits in brain at diagnosis we also determined if chronic  $\gamma$ -secretase inhibition would be effective in the presence of preexisting plaques. Furthermore, to reproduce the effect in an independent mouse model we used APP24 mice with a more diffuse, AD-like plaque morphology. A baseline group was sacrificed at 15 months while other animals were treated during 2 months with daily oral doses of 3 mg/kg LY-411575 or vehicle and sacrificed 6 h after the last substance application. None of the mice died during the treatment but animals receiving LY-411575 also showed the coat color changes described above.

In forebrain of the vehicle group, median A $\beta$ 1-38, 40 and 42 concentrations were 29, 37 and 57% higher than at baseline reflecting the increase in A $\beta$  deposition during the 2 months treatment period (Figure 8, A). In contrast, in the LY-411575 treated group forebrain A $\beta$  remained at baseline level. The olfactory bulb also showed a significant increase of A $\beta$  peptides in the vehicle group, which was largely inhibited

JPET#140327

by substance treatment (not shown). Both forebrain and olfactory bulb already contained a considerable amyloid load at the start of the experiment. To analyze the treatment effect at the onset of plaque formation as in the previous study, A $\beta$  was also determined in pons/medulla oblongata, which contains only very few plaques in 15-17 months old APP24 mice. In this brain region, A $\beta$ 1-38 and 1-40 remained at baseline in the vehicle group suggesting that they are not yet deposited (Figure 8, B). Confirming this notion, LY-411575 reduced both peptides below baseline which indicates turnover. In contrast, A $\beta$ 1-42 was 3-4 times higher in the vehicle group compared to baseline reflecting the formation of early amyloid deposits. This increase was only partially inhibited in LY-411575 treated animals. In CSF average A $\beta$ 42 (0.9 $\pm$ 0.2 pmol/ml) was reduced by 77% (p<0.001, 2-tailed t-test) compared to vehicle treated animals demonstrating that an acute A $\beta$  reduction in CSF still occurs in plaque bearing mice.

The median plaque area of the 15 months old baseline group was 1.8% in neocortex (Figure 9, D). Two months later, it increased to 5% in vehicle treated animals. LY-411575 significantly lowered the neocortical plaque area to 4% corresponding to a reduction of further amyloid deposition by 31% (p=0.01, 2-tailed Mann-Whitney U-test). In caudate putamen, which has a lower amyloid load than neocortex (median plaque area at baseline: 0.16%, vehicle group: 1.6%), LY-411575 had a more pronounced effect (plaque area of 0.5%, corresponding to a 79% reduction of further amyloid deposition, p=0.001, 2-tailed Mann-Whitney U-test). Both, plaque area and treatment effect were similar to the corresponding data for neocortex of the 9 months old APP23 mice described above. The effects on plaque number were comparable to those on plaque area (Figure 9, E) indicating no specific effect on A $\beta$  deposition versus de novo plaque formation. As expected, hardly any plaques could be detected in pons/medulla oblongata. No indication for a removal of preexisting plaques during the two months treatment was found in the brain regions examined.

## Discussion

In this study we have blocked  $\gamma$ -secretase with a potent inhibitor to analyze A $\beta$  turnover and deposition in different APP transgenic mouse models at several stages of amyloid formation. Acute  $\gamma$ -secretase

JPET#140327

inhibition in pre-plaque mice resulted in a dose-dependent decrease of brain A $\beta$  and a corresponding increase in APP CTFs. These effects were more pronounced after subchronic treatment. Mice transgenic for wildtype human APP (APP51/16) responded to the same extent as APP23 carrying the “Swedish” mutation at the BACE cleavage site and APP24, which in addition contain the “London” mutation within the  $\gamma$ -secretase cleavage region.

The inhibitor used, LY-411575, rapidly achieves a high brain concentration (Cirrito et al., 2003; Lanz et al., 2004; methods this study) allowing for kinetic studies. A $\beta$  reached a minimum in brain, CSF and plasma at 4-8 h after substance application and recovered only partially until 24 h indicating a long-lasting inhibitor effect. The turnover of A $\beta$ 40 was generally more rapid than of A $\beta$ 42. CSF A $\beta$ 40 and 42 both declined slightly faster and to a lower level than total, formic acid extracted forebrain A $\beta$ . Their decline in TBS and Triton X-100-soluble brain extracts, however, matched the reduction in CSF well suggesting at least two pools in brain: readily soluble A $\beta$  with a half-life of about 0.7 h (A $\beta$ 40) and 1.7 h (A $\beta$ 42) as well as a less soluble, more stable pool. For both A $\beta$  species the half-lives in the soluble pool and in CSF were almost identical. It is likely that CSF A $\beta$  directly originates from the soluble brain pool, which at least in part is rapidly transported from the parenchyma to CSF and rapidly removed from there. The origin of A $\beta$  from CNS neurons in these mice (Calhoun et al., 1998) further supports this notion. This first direct comparison of the dynamics of the different A $\beta$  pools in brain and CSF indicates that CSF A $\beta$ 40 and A $\beta$ 42 are suited markers for the corresponding peptides in the soluble brain pool.

A rapid decline of detergent extracted brain A $\beta$  after  $\gamma$ -secretase inhibition has also been found in rats (Best et al., 2005), guinea pigs (Anderson et al., 2005) and Tg2576 mice (Barten et al., 2005), where an A $\beta$ 40 half-life of 0.63 h was determined with another  $\gamma$ -secretase (BMS-299897) in very good agreement with this study. As these calculations all assume immediate and complete inhibition of A $\beta$  generation, the real turnover may be even faster. A $\beta$  half-life determinations in human CSF following  $\gamma$ -secretase inhibition are currently not available (see Siemers et al., 2007). Longer A $\beta$  half-lives have been measured in the brain interstitial fluid of LY-411575 treated PDAPP mice by *in vivo* microdialysis (~2 h for young

mice (Cirrito et al., 2003)) and in human CSF with an isotopic labeling method (clearance rate ~8% per hour, corresponding half-life ~8-9 h (Bateman et al., 2006)). The different techniques used may have contributed to the discrepancies.

The half-life of plasma A $\beta$ 40 ( $\leq 0.5$  h) was shorter than in brain and CSF in line with the faster turnover observed in other APP transgenic mouse models (Wong et al., 2004; Barten et al., 2005; Anderson et al., 2005). In plasma A $\beta$  returned to baseline levels more rapidly than in brain and CSF although the human A $\beta$  measured originates from brain. The APP overexpression in APP23 mice may have overloaded the export system to plasma. Under such conditions a minor recovery of brain A $\beta$  is sufficient to completely restore the plasma A $\beta$ . Conversely, a lag phase is expected at the beginning of the decline. A rebound increase in plasma A $\beta$  after  $\gamma$ -secretase inhibitor treatment has been described for humans (e.g. Siemers et al., 2007), guinea pigs (Lanz et al., 2006) and in one (Prasad et al., 2007) but not other (e.g. Wong et al., 2004; Barten et al., 2005; Anderson et al., 2005) APP transgenic mouse studies. It is not accompanied by a change in brain or CSF A $\beta$  suggesting a peripheral origin (as discussed in Siemers et al., 2007). We have not detected a rebound increase in plasma A $\beta$ , perhaps because human A $\beta$  in APP23 originates almost exclusively from brain (Calhoun et al., 1998) but other possibilities (e.g. rebound between 24 and 53 h) cannot be excluded.

An estimate of the A $\beta$  production rate in APP23 mice was obtained from its rate of removal, which is equal assuming A $\beta$  steady-state in pre-plaque mice. The production rate was independently estimated from the A $\beta$  accumulation in plaque bearing APP23 mice supposing that all produced A $\beta$  is deposited. The values obtained with these entirely different approaches were remarkably similar (A $\beta$ 40: 9.3 and 11 pmol/g/h, A $\beta$ 42: 0.7 and 1.5 pmol/g/h) but in both cases higher for plaque-bearing mice. It, therefore, seems possible that A $\beta$  generation increases during plaque formation. Moreover, the presence of A $\beta$  in CSF of plaque-bearing mice demonstrates its incomplete deposition and suggests even higher actual production rates.

Together with the A $\beta$  reduction, acute  $\gamma$ -secretase inhibition caused a strong elevation of the APP C-

JPET#140327

terminal fragments from which the half-lives of C99 and C83 for degradation by  $\gamma$ -secretase were estimated as about 0.4 and 0.1 h, respectively. The reason for this difference is not understood but may be related to different intracellular locations of both fragments. The Swedish mutation as present in APP23 mice is thought to elevate BACE1 cleavage and C99 generation in secretory compared to endocytic compartments (Haass et al., 1995). Future studies will have to show if the same half-lives are obtained with wild-type APP transgenic mice. The continuous increase of C83 during the phase of  $\gamma$ -secretase inhibition indicated that this enzyme serves as its primary degradation pathway in brain neurons. In contrast, the decrease in C99 accumulation with time suggests that this fragment may undergo degradation by proteases different from  $\gamma$ -secretase or that its generation is reduced by feedback mechanisms. It also remains to be determined whether  $\gamma$ -secretase inhibition of wild-type mice, which express far less APP, leads to similar increases in APP CTFs.

Chronic inhibition of  $\gamma$ -secretase in a preventive setting, where APP23 mice had been treated between 6 and 9 months of age, resulted in an 80% reduction of the amyloid plaque area as well as of all three A $\beta$  peptides analyzed (A $\beta$ 1-38, 1-40 and 1-42). The number of plaques was less reduced consistent with a smaller effect on de novo plaque formation than on A $\beta$  deposition. Comparable effects have been obtained in PDAPP mice (May et al., 2001). In a clinically more relevant therapeutic paradigm, plaque bearing APP24 mice were treated from 15 to 17 months of age. Forebrain A $\beta$  levels remained at baseline, while the amyloid load increased, yet about 30% less than in the vehicle group. Caudate/putamen, a region with a low plaque development, showed a much stronger reduction of the amyloid load than forebrain of the same mice indicating that the efficacy differences were not age-related. Instead they inversely correlated with the initial amyloid load (Table 1) irrespective of the brain region and amyloid type. These results demonstrate that inhibition of A $\beta$  generation can effectively slow down further amyloid formation in brains already containing plaques, even when the block of A $\beta$  generation is not complete. The reduction is region-specific insofar as a strong effect can be expected for areas with a low amyloid load while it may be much smaller in amyloid laden regions of the same brain. In agreement with

JPET#140327

our data an about 50% reduction of plaques was observed after 3 months treatment of aged Tg2576 mice with the  $\gamma$ -secretase inhibitor MRK-560 (Best et al., 2007). Our studies did not provide evidence for a clearance of preexisting plaques in any brain region. Even chronic suppression of APP expression in transgenic mice during 6 months only halted further amyloid deposition (Jankowsky et al., 2005).

At 15 to 17 months plaque formation just starts in pons/medulla oblongata of APP24 mice. In this region, the last  $\gamma$ -secretase inhibitor treatment acutely reduced A $\beta$ 1-38 and A $\beta$ 1-40 below baseline and vehicle levels similar to forebrain of pre-plaque animals. In contrast, A $\beta$ 1-42 increased in the vehicle group indicating deposition, which was partially reduced by the treatment. This supports the notion that A $\beta$ 42 initiates deposition in vivo and suggests some independence between the A $\beta$  isoforms, at least initially. In line with these results, CSF A $\beta$  from aged mice with a high brain amyloid load showed a similar reduction after the last  $\gamma$ -secretase inhibitor dose as in acutely treated pre-plaque mice. CSF A $\beta$ , therefore, seems a suited marker to assess treatment effects on A $\beta$  generation in amyloid bearing brain.

As suggested by the acute studies, chronic  $\gamma$ -secretase inhibition caused dramatic elevation of APP C-terminal fragments. Histological analysis of three months treated mice showed that CTFs accumulated primarily in nerve fibers, rather than in cell bodies. Toxic properties have repeatedly been attributed to these fragments (Lee et al., 2006) and their accumulation may lead to side effects. However, the major contribution to side effects of  $\gamma$ -secretase inhibitors is thought to originate from the interference with intestinal and lymphatic cell differentiation associated with the inhibition of Notch cleavage (Searfoss et al., 2003; Wong et al., 2004). Recently, the coat color changes have also been linked to the inhibition of Notch processing (Schouwey and Beermann, 2008). Interestingly, alterations in hair color have also been observed in a clinical study with  $\gamma$ -secretase inhibitor LY-450139 (E. Siemers at the Alzheimer's Association Prevention Conference 2007; [http://www.alz.org/preventionconference/pc2007/releases/-61107\\_130pm\\_latebreak.asp](http://www.alz.org/preventionconference/pc2007/releases/-61107_130pm_latebreak.asp)).

Independent of the potential liabilities of  $\gamma$ -secretase inhibition, our study describes typical features of A $\beta$  turnover and deposition in vivo, which are important to design studies for testing A $\beta$  lowering

JPET#140327

approaches. It demonstrates the suitability of APP transgenic mice as translational models for the evaluation of such strategies.

### **Acknowledgments**

We thank Dr. Paolo Paganetti for antiserum NT11 and antibodies 25H10 and 29C12, and Albert Enz for the determination of LY-411575 compound concentrations.



## References

- Anderson JJ, Holtz G, Baskin PP, Turner M, Rowe B, Wang B, Kounnas MZ, Lamb BT, Barten D, Felsenstein K, McDonald I, Srinivasan K, Munoz B and Wagner SL (2005) Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. *Biochem Pharmacol* **69**:689-698.
- Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, Polson CT, Wang J, Roberts SB, Hendrick JP, Anderson JJ, Loy JK, Denton R, Verdoorn TA, Smith DW and Felsenstein KM (2005) Dynamics of  $\beta$ -Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of  $\beta$ -Amyloid Precursor Protein Transgenic Mice Treated with a  $\gamma$ -Secretase Inhibitor. *J Pharmacol Exp Ther* **312**:635-643.
- Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE and Holtzman DM (2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. *Nat Med* **12**:856-861.
- Baumann K, Paganetti PA, Sturchler-Pierrat C, Wong C, Hartmann H, Cescato R, Frey P, Yankner BA, Sommer B and Staufenbiel M (1997) Distinct processing of endogenous and overexpressed recombinant presenilin 1. *Neurobiol Aging* **18**:181-189.
- Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, Lewis HD, Pattison C, Reilly M, Harrison T, Shearman MS, Williamson TL and Attack JR (2005) Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. *J Pharmacol Exp Ther* **313**:902-908.
- Best JD, Smith DW, Reilly MA, O'donnell R, Lewis HD, Ellis S, Wilkie N, Rosahl TW, Laroque P, Boussiquet-Leroux C, Churcher I, Attack JR, Harrison T and Shearman MS (2007) The novel  $\gamma$ -secretase inhibitor MRK-560 reduces amyloid plaque deposition without evidence of Notch-related pathology in the Tg2576 mouse. *J Pharmacol Exp Ther* **320**:552-558.

- Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B and Jucker M (1998) Neuron loss in APP transgenic mice. *Nature* **395**:755-756.
- Churcher I, Beher D, Best JD, Castro JL, Clarke EE, Gentry A, Harrison T, Hitzel L, Kay E, Kerrad S, Lewis HD, Morentin-Gutierrez P, Mortishire-Smith R, Oakley PJ, Reilly M, Shaw DE, Shearman MS, Teall MR, Williams S and Wrigley JD (2006) 4-substituted cyclohexyl sulfones as potent, orally active gamma-secretase inhibitors. *Bioorg Med Chem Lett* **16**:280-284.
- Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB and Holtzman DM (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. *J Neurosci* **23**:8844-8853.
- Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George HP and Selkoe DJ (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. *Nat Med* **3**:67-72.
- Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS and Marquis KL (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. *J Neurosci* **25**:8898-8902.
- Dash PK, Moore AN and Orsi SA (2005) Blockade of gamma-secretase activity within the hippocampus enhances long-term memory. *Biochem Biophys Res Commun* **338**:777-782.
- Donoviel DB, Hadjantonakis AK, Ikeda M, Zheng H, Hyslop PS and Bernstein A (1999) Mice lacking both presenilin genes exhibit early embryonic patterning defects. *Genes Dev* **13**:2801-2810.
- Dovey HF, John V, Anderson JP, Chen LZ, de Saint AP, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp

- GM, Thorsett ED, Tung JS, Wu J, Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK, Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Little SP, Mabry TE, Miller FD and Audia JE (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. *J Neurochem* **76**:173-181.
- Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. *Nat Med*. **1**:1291-1296.
- Hardy J and Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* **297**:353-356.
- Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M, Mathews PM and Jucker M (2004) Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. *Nat Neurosci* **7**:954-960.
- Hyde LA, McHugh NA, Chen J, Zhang Q, Manfra D, Nomeir AA, Josien H, Bara T, Clader JW, Zhang L, Parker EM and Higgins GA (2006) Studies to investigate the in-vivo therapeutic window of the  $\gamma$ -secretase inhibitor LY411,575 in the CRND8 mouse. *J Pharmacol Exp Ther* **319**:1133-1143.
- Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG and Borchelt DR (2005) Persistent Amyloidosis following Suppression of Abeta Production in a Transgenic Model of Alzheimer Disease. *PLoS Med* **2**:e355.
- Klafki HW, Wiltfang J and Staufenbiel M (1996) Electrophoretic separation of betaA4 peptides (1-40) and (1-42). *Anal Biochem* **237**:24-29.
- Lanz TA, Hosley JD, Adams WJ and Merchant KM (2004) Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). *J Pharmacol Exp Ther* **309**:49-55.

- Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KE, Finley JE, Fei Q, Ebbinghaus CF, Chen YL, Spracklin DK, Tate B, Geoghegan KF, Lau LF, Aupein DD and Schachter JB (2006) Concentration-dependent modulation of A $\beta$  in vivo and in vitro using the  $\gamma$ -secretase inhibitor, LY-450139. *J Pharmacol Exp Ther* **319**:924-933.
- Lee KW, Im JY, Song JS, Lee SH, Lee HJ, Ha HY, Koh JY, Gwag BJ, Yang SD, Paik SG and Han PL (2006) Progressive neuronal loss and behavioral impairments of transgenic C57BL/6 inbred mice expressing the carboxy terminus of amyloid precursor protein. *Neurobiol Dis* **22**:10-24.
- Li J, Fici GJ, Mao CA, Myers RL, Shuang R, Donoho GP, Pauley AM, Himes CS, Qin W, Kola I, Merchant KM and Nye JS (2003) Positive and negative regulation of the gamma-secretase activity by nicastrin in a murine model. *J Biol Chem* **278**:33445-33449.
- May PC, Altstiel LD, Bender MH, Boggs LN, Calligaro DO, Fuson KS, Gitter BD, Hyslop PA, Jordan WH, Li WY, Mabry TE, Mark RJ, Ni B, Nissen JS, Porter WJ, Sorgen SG, Su Y, Audia JE, Dovey HF, Games D, John V, Freedman S, Guido T, Johnson-Wood KL, Khan K, Latimer LH, Lieberburg IM, Seubert PA, Soriano F, Thorsett ED and Schenk DB (2001) Marked reduction of Abeta accumulation and beta-amyloid plaque pathology in mice upon chronic treatment with a functional gamma-secretase inhibitor. *Soc Neurosci Abstr* **27**:681
- Prasad CV, Zheng M, Vig S, Bergstrom C, Smith DW, Gao Q, Yeola S, Polson CT, Corsa JA, Guss VL, Loo A, Wang J, Slecicka BG, Dangler C, Robertson BJ, Hendrick JP, Roberts SB and Barten DM (2007) Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): A gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease. *Bioorg Med Chem Lett* **17**:4006-4011.
- Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RG and Shen J (2005) Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. *J Neurosci* **25**:6755-6764.

- Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D and Younkin S (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nat Med* **2**:864-870.
- Schouwey K and Beermann F (2008) The Notch pathway: hair graying and pigment cell homeostasis. *Histol Histopathol* **23**:609-619.
- Schrader-Fischer G and Paganetti PA (1996) Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. *Brain Res* **716**:91-100.
- Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC and Ryan TP (2003) Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. *J Biol Chem* **278**:46107-46116.
- Selkoe D and Kopan R (2003) Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. *Annu Rev Neurosci* **26**:565-597.
- Shearman MS, Behr D, Clarke EE, Lewis HD, Harrison T, Hunt P, Nadin A, Smith AL, Stevenson G and Castro JL (2000) L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. *Biochemistry* **39**:8698-8704.
- Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR and May PC (2007) Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-beta After Inhibition of gamma-Secretase. *Clin Neuropharmacol* **30**:317-325.
- Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M and Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. *Proc Natl Acad Sci U S A* **94**:13287-13292.
- Tandon A and Fraser P (2002) The presenilins. *Genome Biol* **3**:3014.

Wolfe MS (2006) The gamma-secretase complex: membrane-embedded proteolytic ensemble.

*Biochemistry* **45**:7931-7939.

Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA and Parker EM (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. *J Biol Chem* **279**:12876-12882.

Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, Chen HY, Price DL, Van der Ploeg LH and Sisodia SS (1997) Presenilin 1 is required for Notch1 and DIII1 expression in the paraxial mesoderm. *Nature* **387**:288-292.

Zhao G, Cui MZ, Mao G, Dong Y, Tan J, Sun L and Xu X (2005) gamma-Cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. *J Biol Chem* **280**:37689-37697.

## Legends for Figures

### **Figure 1 Kinetics of A $\beta$ reduction and CTF accumulation in pre-plaque APP23 mice after application of LY-411575.**

Male APP23 mice (hAPP, Swedish mutation, 6-8 per group) were treated with 10 mg/kg LY-411575 or vehicle at 4 months of age and sacrificed at 0.5, 1, 2, 4, 6, 8, 24 or 53 h. A $\beta$  in forebrain and CSF was determined by ELISA while an electrochemoluminescence-linked immunoassay was used for plasma; C99 and C83 were measured by Western blotting (antiserum APP-C8). A: Time-dependent reduction of total (formic acid extracted), Triton X-100 soluble and TBS-soluble A $\beta$ 40 in forebrain and total A $\beta$ 40 in CSF and plasma. B: Comparison of total A $\beta$ 40 and A $\beta$ 42 reductions in forebrain. C: Accumulation of C99 and C83 in forebrain. Significant differences to the vehicle group are indicated by asterisks (ANOVA and Dunnett's test;  $p < 0.05$ : \*;  $p < 0.01$ : \*\*;  $p < 0.001$ : \*\*\*). In forebrain of vehicle treated animals, total A $\beta$ 40 and A $\beta$ 42 concentrations were  $21 \pm 0.3$  pmol/g and  $6 \pm 0.3$  pmol/g (average  $\pm$  standard error). Triton X-100 and TBS solubilized about 30% and 2% of total A $\beta$ 40. In CSF and plasma A $\beta$ 40 was at 17% and 0.4% of the forebrain level, respectively.

### **Figure 2 Reduction of A $\beta$ in pre-plaque APP24 and APP51/16 mice after LY-411575 treatment.**

Female APP24 mice (hAPP, Swedish and London mutations) at 4 months of age and male APP51/16 mice (hAPP, wild-type) at 6 months received a single dose of LY-411575 (10 mg/kg) or vehicle and were sacrificed 1 h (APP24 only) and 6 h thereafter (5-6 per group). Following extraction of forebrain homogenates with formic acid (FA, total) or 1% Triton X-100 (Tx100), A $\beta$  concentrations in forebrain were determined by ELISA (FA) or electrochemiluminescence-linked immunoassay (Tx100). A: In APP24 forebrain, A $\beta$ 40 and A $\beta$ 42 were significantly reduced in a time-dependent manner. The reduction was more pronounced for A $\beta$ 40 than for A $\beta$ 42 and stronger for Triton X-100 soluble than for total A $\beta$ . The A $\beta$ 40 reduction in APP51/16 mice was similar to APP24. B: The fitted curves of A $\beta$  decrease in APP24 mice were used to calculate half-lives ( $t_{1/2}$ ) and rate constants for the reduction ( $k$ ) of total (FA)

JPET#140327

and Triton X-100 (Tx100) soluble forebrain and CSF A $\beta$ . The A $\beta$ 42 reduction in CSF was very similar to Triton extracts of forebrain. Significant differences between treatment groups and vehicle are indicated by asterisks (ANOVA and Dunnett's test for APP24, t-test for APP51/16; p<0.05: \*; p<0.01: \*\*; p<0.001: \*\*\*; n.d.: below detection limit). In forebrain of vehicle treated APP24 animals, total A $\beta$ 40 and A $\beta$ 42 concentrations were 6.7 $\pm$ 0.5 pmol/g and 6.3 $\pm$ 0.7 pmol/g (average $\pm$ standard error). Triton X-100 solubilized about 58% of total A $\beta$ 40 and 22% of total A $\beta$ 42. In CSF A $\beta$ 42 was at 16% of the forebrain level. In forebrain of vehicle treated APP51/16 mice, the total A $\beta$ 40 concentration was 7 $\pm$ 0.6 pmol/g.

**Figure 3 A $\beta$  and CTF halflives in pre-plaque APP23 mice.**

Data from Figure 1 were used: A: Decrease of A $\beta$  during the first 4 h after substance application. The fitted curves were used to calculate half-lives ( $t_{1/2}$ ) and rate constants for the reduction ( $k$ ) of total (FA) and Triton X-100 (Tx100) soluble A $\beta$ 40 in forebrain, CSF and plasma. Please note that the plasma data did not follow a first order decline from 0 h on. The brain A $\beta$ 42 half-life could not be determined reliably during the 4 h period. B: While accumulation of C99 was highest between 0.5 and 1 h after substance treatment and leveled off thereafter, C83 accumulated linearly between 0.5 and 8 h (Pearson correlation coefficient p=0.96). Halflives of C99 (0.4 h) and C83 (0.1 h) were calculated from accumulation in the highlighted time interval (0.5 – 2 h after LY-411575 treatment).

**Figure 4 C-terminal APP-fragments after acute, subchronic and chronic treatment of APP23 mice with LY-411575.**

Animals received a single, 14 d or 3 months treatment with LY-411575. A: Western blot of representative animals demonstrating that APP C-terminal fragments were increased compared to controls (no) already after a single dose and raised further upon prolonged treatment (14 days and 3 months). After chronic treatment (3 mo), new bands were detected (see bracket with asterisk), which may represent APP degradation products or aggregated CTFs. Animals sacrificed 6 h after substance treatment are shown. B: Even after chronic treatment with LY-411575 (3 months), the increase of C99 in forebrain partially normalized towards control values 24 h after the last treatment (ANOVA and Tukey's test; p<0.01: \*\*;



p<0.001: \*\*\*). C: Dephosphorylation with E.coli  $\lambda$ -phosphatase revealed that the main accumulating CTF of APP was C83. C89 also accumulated slightly more than C99 (compare second to last lane). Western blots were done with antiserum APP-C8.

**Figure 5 Chronic LY-411575 treatment of APP23 mice during the early stage of plaque formation reduced forebrain and CSF A $\beta$ .**

Female APP23 mice (20 per group) were treated for 3 months with LY-411575 starting at an age of 6 months and sacrificed at 6 h and 24 h after the last treatment. A $\beta$  was analyzed by Western blotting. A: Median A $\beta$ 1-38, 40 and 42 concentrations in forebrain were reduced by 81%, 85% and 77% compared to control animals. Data from both sacrifice points were combined. B: A $\beta$  species in CSF were decreased compared to vehicle 6 h after drug application and normalized partially towards control values 24 h after the treatment. Each symbol represents one animal. The lines shows the position of medians (forebrain) or average (CSF), respectively (determined by Western blotting with antibody 6E10, forebrain: Mann-Whitney U-test; p<0.0001: \*\*\*; CSF: ANOVA and Dunnett's test; p<0.05: \*; p<0.01: \*\*; p<0.001: \*\*\*).

**Figure 6 Chronic LY-411575 treatment during the early stage of plaque formation reduced amyloid plaque deposition.**

At 9 months, amyloid plaques in APP23 brains are mainly restricted to the neocortex, medium in size (10-50  $\mu$ m diameter) and mostly of the compact type. A: After treatment from 6 to 9 months, the plaque area in neocortex was reduced by 80%. B: The number of plaques per mm<sup>2</sup> decreased by 66% (Mann-Whitney U-test: p<0.0001). Each symbol represents one animal. The lines indicate the median. C, D: Representative forebrain sections stained for amyloid plaques (arrowheads) using antibody NT11. E, F: Intracellular A $\beta$  in cortical pyramidal cells of substance treated animals formed clusters strongly stained with the A $\beta$  antiserum NT11 (arrows in F) and with antibodies specific for A $\beta$ 40 and A $\beta$ 42 (supplementary data, Figure 4S). No difference was found between animals sacrificed 6 or 24 h after the last treatment. In control animals intracellular A $\beta$  was distributed more homogenously within neurons (arrows in E). C, D: Bar 500  $\mu$ m; E, F: Bar = 50  $\mu$ m

JPET#140327

**Figure 7 Altered APP immunostaining in brain after chronic LY-411575 treatment of APP23 mice.**

APP23 mice were treated for 3 months with LY-411575. A-D: The C-terminal antibody APP-C8 revealed a reduced staining in neuronal cell bodies compared to vehicle (B, D versus A, C), which was most evident in neocortex layer V (compare A to B, Cx V) and hippocampus (compare C to D). In the CA3 region of the hippocampus, APP-C8 stained mostly neuronal cell bodies in control mice, while nerve fibers were stained in LY-411575 treated animals (insets in C and D). Staining of nerve fibers with APP-C8 was strongly increased in several other brain regions (stratum oriens of CA1, Or; outer and inner neocortical layers, Cx I-II and Cx VI; retrosplenial cortex, RS; subiculum, Sub; mossy fibers, mF; polymorph layer of the dentate gyrus, PoDG; compare A to B). E, F: The reduction of cell body APP staining was also seen with antiserum 474 directed against an epitope in the N-terminus of APP. APP474 did not stain fibers indicating that the fiber staining of APP-C8 represents accumulated C-terminal APP fragments. Boxes in A and B indicate the approximate positions of the higher magnifications shown in C to F. B: Bar = 500  $\mu$ m (also for A); F: Bar = 50  $\mu$ m (also for D-E). Large boxes in C to F are insets at higher magnification.

**Figure 8 Reduced accumulation of A $\beta$  in brains of plaque bearing APP24 mice during chronic treatment with LY-411575.**

Female APP24 mice were treated daily with 3 mg/kg LY-411575 or vehicle for 2 months starting at the age of 15 months, when these mice carry a moderate neocortical amyloid load. Animals (15 per group) were sacrificed at baseline (15 months) and 6 h after the last dose (17 months). A: A $\beta$ 1-38, 40 and 42 in forebrain remained at baseline in substance treated mice, while in the vehicle treated group A $\beta$ 1-40 and 42 increased as determined by quantitative MALDI-TOF of SDS-extracted and immunoprecipitated A $\beta$ . B: In pons/medulla oblongata, where only very few amyloid plaques are found at 17 months, LY-411575 reduced A $\beta$ 1-38 and 1-40 compared to baseline. The increase of A $\beta$ 1-42 was only partially inhibited consistent with the formation of early amyloid deposits. Each symbol represents one animal. Lines

JPET#140327

indicate the median. Significant differences between groups are indicated by asterisks (Kruskal-Wallis test and Tukey's post hoc test on ranks;  $p < 0.05$ : \*;  $p = 0.01$ : \*\*;  $p < 0.001$ : \*\*\*).


**Figure 9 Reduced plaque formation in brains of APP24 mice with moderate amyloid load during chronic treatment with LY-411575.**

APP24 mice were treated from 15 to 17 months with 3 mg/kg LY-411575. A-C: Shown are representative brain sections from a baseline animal at 15 months (A) and from 17 months old treated (B) or vehicle (C) animals. LY-411575 reduced the amyloid deposition. Amyloid plaques were quantified in highlighted regions shown in C (neocortex, Cx and caudate putamen, CPu). C: Bar = 1 mm (also for A and B). D, E: The reduction of amyloid deposition (D: plaque area, E: plaque number) was more pronounced in caudate putamen than in neocortex. Each symbol represents one animal. The lines shows the position of medians. Significant differences are indicated by asterisks (Kruskal-Wallis test and Tukey's post hoc test on ranks;  $p < 0.05$ : \*;  $p < 0.01$ : \*\*;  $p = 0.001$ : \*\*\*). The amount of inhibition of plaque formation as percent of the difference between baseline and vehicle treated group is indicated.

**Table 1:** The reduction of amyloid accumulation by chronic  $\gamma$ -secretase inhibition inversely correlates with the initial amyloid load

Line	Treatment	Brain region	Initial plaque area	Efficiency	
			Median	Average	Median
APP23	6-9 mo	neocortex	<0.1%	- 82%	-80%
APP24	15-17 mo	caudate/putamen	0.16%	- 66%	-79%
APP24	15-17 mo	neocortex	1.8%	- 41%	-31%

Figure 1



## Figure 2




Figure 3




Figure 4






Figure 5









Figure 6



# Figure 7




Figure 8




Figure 9

